Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, double-blind, randomized study to evaluate the safety and efficacy of sitagliptin compared with metformin in patients with type 2 diabetes mellitus with inadequate glycemic control

Next Previous
X
Search
Trial Profile

A multicenter, double-blind, randomized study to evaluate the safety and efficacy of sitagliptin compared with metformin in patients with type 2 diabetes mellitus with inadequate glycemic control

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sitagliptin (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme

    • Most Recent Events

    • 12 May 2019 This trial has been completed in Bulgaria as per European Clinical Trials Database record.
    • 06 Nov 2012 Planned number of patients changed from 1000 to 1034.
    • 11 Sep 2008 Results from the 50-week extension phase presented at EASD

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top